tag:blogger.com,1999:blog-344855792009-02-21T02:33:41.467-08:00CPTech Brownbag EventsJulie Patelhttp://www.blogger.com/profile/09449508724143352389noreply@blogger.comBlogger6125tag:blogger.com,1999:blog-34485579.post-1164731605539968962006-11-28T08:27:00.000-08:002006-11-28T08:36:51.140-08:00Michael Abramowicz on "Perfecting Patent Prizes".<span style="font-family:'PrimaSans BT,Verdana,sans-serif';"><span style="font-style: italic;">CPTech is hosting a brown bag lunch seminar by Michael Abramowicz on </span><span style="font-style: italic;">"Perfecting Patent Prizes."</span><br /><br /><span style="font-weight: bold;">Who:</span> George Washington University Law Professor Michael Abramowicz<br /><br /><span style="font-weight: bold;">What: </span>Brown Bag Lunch on "Perfecting Patent Prizes"<br /><br /><span style="font-weight: bold;">When:</span> 12:30-2:00pm on Tuesday, December 12th<br /><br /><span style="font-weight: bold;">Where:</span> CPTech - 1621 Connecticut Ave. NW, Washington DC 20009.<br /><br /><span style="font-weight: bold;">Details:</span><br /></span><div style="text-align: justify;"><span style="font-family:'PrimaSans BT,Verdana,sans-serif';">Several recent brown bag speakers have discussed the potential of using prizes in lieu of patents to promote medical innovation. While reaction to such proposals has been positive, some have expressed the </span><span style="font-family:'PrimaSans BT,Verdana,sans-serif';">concern that with innovation prize systems, "the devil is in the details." In this brown bag seminar, Michael Abramowicz, author of </span><span style="font-family:'PrimaSans BT,Verdana,sans-serif';">the lengthy article "Perfecting Patent Prizes (see link below)," will </span><span style="font-family:'PrimaSans BT,Verdana,sans-serif';">offer his views on sticky issues in the implementation of an </span><span style="font-family:'PrimaSans BT,Verdana,sans-serif';">innovation prize system. He argues that there is no perfect formula </span><span style="font-family:'PrimaSans BT,Verdana,sans-serif';">or algorithm for determining the size of prizes, but that a prize </span><span style="font-family:'PrimaSans BT,Verdana,sans-serif';">system is nonetheless worth pursuing because it could increase social </span><span style="font-family:'PrimaSans BT,Verdana,sans-serif';">welfare significantly by eliminating deadweight loss. Professor </span><span style="font-family:'PrimaSans BT,Verdana,sans-serif';">Abramowicz will present his proposals for implementing an innovation </span><span style="font-family:'PrimaSans BT,Verdana,sans-serif';">prize system and discuss what he considers to be the strengths and </span><span style="font-family:'PrimaSans BT,Verdana,sans-serif';">weakness of the system proposed in Senator-elect Bernie Sanders' </span><span style="font-family:'PrimaSans BT,Verdana,sans-serif';">Medical Innovation Prize Fund Act (H.R. 417).</span><br /><br /><span style="font-family:'PrimaSans BT,Verdana,sans-serif';">Professor Abramowicz is a graduate of Yale Law School, where he </span><span style="font-family:'PrimaSans BT,Verdana,sans-serif';">served as executive editor of the Yale Law Journal. After graduating, </span><span style="font-family:'PrimaSans BT,Verdana,sans-serif';">he clerked for the U.S. Fifth Circuit Court of Appeals. He teaches </span><span style="font-family:'PrimaSans BT,Verdana,sans-serif';">and does research on intellectual property, and is published in </span><span style="font-family:'PrimaSans BT,Verdana,sans-serif';">journals including the California Law Review, Columbia Law Review, </span><span style="font-family:'PrimaSans BT,Verdana,sans-serif';">Iowa Law Review, Michigan Law Review, Stanford Law Review, UCLA Law</span><br /><span style="font-family:'PrimaSans BT,Verdana,sans-serif';">Review, University of Chicago Law Review, Vanderbilt Law Review, Yale </span><span style="font-family:'PrimaSans BT,Verdana,sans-serif';">Journal on Regulation, and Yale Law Journal.</span><br /><br /><span style="font-family:'PrimaSans BT,Verdana,sans-serif';">Michael's presentation will be based on his 2003 paper:</span><br /><span style="font-family:'PrimaSans BT,Verdana,sans-serif';">"Perfecting Patent Prizes," Vanderbilt Law Review (56): 115.</span><br /><span style="font-family:'PrimaSans BT,Verdana,sans-serif';"><a target="l" href="http://www.law.gmu.edu/faculty/papers/wpDetail.php?wpID=120">http://www.law.gmu.edu/faculty/papers/wpDetail.php?wpID=120</a></span><br /><br /><span style="font-family:'PrimaSans BT,Verdana,sans-serif';">If you would like to join us for Michael Abramowicz's brown bag </span><span style="font-family:'PrimaSans BT,Verdana,sans-serif';">seminar, please RSVP your name, title, organization and contact </span><span style="font-family:'PrimaSans BT,Verdana,sans-serif';">details to: ben.krohmal@cptech.org or </span><span style="font-family:'PrimaSans BT,Verdana,sans-serif';">202.332.2670.</span><br /></div><span style="font-family:'PrimaSans BT,Verdana,sans-serif';"><br />Benjamin Krohmal<br />Medical Innovation Fund Project Director<br />Consumer Project on Technology<br />Tel: +1-202-332-2670 ex. 14<br />Fax: +1-202-332-2673<br />ben.krohmal@cptech.org<br /></span><div class="blogger-post-footer"><img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/34485579-116473160553996896?l=cptechstaff.blogspot.com'/></div>Julie Patelhttp://www.blogger.com/profile/09449508724143352389noreply@blogger.com0tag:blogger.com,1999:blog-34485579.post-1162927913997096962006-11-07T11:30:00.000-08:002006-11-10T15:59:59.023-08:00Next Steps and Strategies on Bilateral Free Trade Agreements<pre>The Consumer Project on Technology (CPTech) is hosting a post-<br />election brown bag lunch seminar and strategy session on "Next Steps<br />and Strategies on Bilateral Free Trade Agreements."<br /><br />Date: Thursday, November 16th, 2006.<br />Time: 12-1:30pm<br />Venue: 1621 Connecticut Avenue Suite 500, Washington, DC 20009<br /><br />The session will feature brief presentations on the results of<br />previous FTA's, ongoing FTA negotiations, and possible future<br />directions by the following panelists:<br /><br />Jamie Love of CPTech<br />Rob Weissman of Essential Action<br />Rohit Malpani of Oxfam<br />Gaelle Krikorian of CRESP,<br />Fabiana Jorge of MFJ international,<br />Asia Russell of Health GAP,<br />Brook Baker of Health GAP, and<br />Matthew Kavanagh of Global Justice<br /><br />Following the presentations there will be general discussion and<br />coordination on strategies for addressing FTA's in light of the<br />results of the U.S. mid-term elections and the possible expiration of<br />TPA in July.<br /><br />This will be an important session for those working on issues in<br />trade and access to medicine.<br /><br />If you would like to join us for the FTA brown bag, please RSVP your<br />name, title, and organization to <a href="http://www.questmail.futurequest.net/src/compose.php?send_to=ben.krohmal%40cptech.org">ben.krohmal@cptech.org</a> or 202 332 2673.<br /><br />Benjamin Krohmal<br />Medical Innovation Fund Project Director<br />Consumer Project on Technology<br />Tel: +1-202-332-2670 ex. 14<br />Fax: +1-202-332-2673<br /><a href="http://www.questmail.futurequest.net/src/compose.php?send_to=ben.krohmal%40cptech.org">ben.krohmal@cptech.org</a><br /><br /><br /><br /><br /></pre><div class="blogger-post-footer"><img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/34485579-116292791399709696?l=cptechstaff.blogspot.com'/></div>Julie Patelhttp://www.blogger.com/profile/09449508724143352389noreply@blogger.com0tag:blogger.com,1999:blog-34485579.post-1160771644526588422006-10-13T13:26:00.000-07:002006-10-13T13:34:04.550-07:00Compulsory Licensing in Ghana - the Continuing Barriers to Affordable MedicinesThe Consumer Project on Technology (CPTech) is hosting a seminar by<br /><span style="font-weight: bold;">Noah Novogrodsky on </span><span style="font-weight: bold;">"Compulsory Licensing in Ghana - the Continuing Barriers to Affordable Medicines"</span><br /><br />Date: Tuesday November 7, 2006<br />Time: 12:00-2pm<br />Venue: 1621 Connecticut Avenue Suite 500, Washington, DC 20009<br />RSVP: judit.rius (at) cptech.org or 202 332 2670<br /><br />Professor Noah Novogrodsky will present on <span style="font-weight: bold;">"Compulsory Licensing in Ghana - the Continuing Barriers to Affordable Medicines"</span>. His presentation will describe the painfully slow effort to implement the WTO August 30th 2003 Decision through Canadian export legislation and Ghana's Patent Act.<br /><br />Professor <a href="http://www.law.georgetown.edu/curriculum/tab_faculty.cfm?Status=Faculty&FacultyID=2221">Novogrodsky</a> is a Visiting Professor of Law at Georgetown University Law Center and the Director of the University of Toronto Faculty of Law International Human Rights Program. Noah Novogrodsky joined the University of Toronto Faculty of Law in 2002 and in September 2003, he founded Canada's first international human rights clinic at the Faculty. For each of the past three years, Professor Novogrodsky has taught a seminar titled “The HIV/AIDS in Africa Project” in connection with the work of Stephen Lewis, the UN Secretary-General’s Special Envoy on HIV/AIDS in Africa. Professor Novogrodsky has also been an organizer of the University of Toronto-based Access to Drugs Initiative. Professor Novogrodsky’s current research agenda focuses on the HIV/AIDS pandemic as a threat to human security.<div class="blogger-post-footer"><img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/34485579-116077164452658842?l=cptechstaff.blogspot.com'/></div>Julie Patelhttp://www.blogger.com/profile/09449508724143352389noreply@blogger.com0tag:blogger.com,1999:blog-34485579.post-1159205327227818742006-09-25T10:26:00.000-07:002006-09-25T10:32:42.780-07:00“Is a Medical Innovation Prize Fund Compatible with Patient-Based Evidence?”The Consumer Project on Technology (CPTech) is hosting a brown bag<br />lunch seminar by <span style="font-weight: bold;">Peter Pitts: “Is a Medical Innovation Prize Fund </span><br /><span style="font-weight: bold;">Compatible with Patient-Based Evidence?”</span><br /><br /><span style="font-weight: bold;">Date: Thursday, November 9th, 2006</span><br /><br /><span style="font-weight: bold;">Time: 12-1:30pm</span><br /><br /><span style="font-weight: bold;">Venue: 1621 Connecticut Avenue Suite 500, Washington, DC 20009</span><br /><br />Recent CPTech seminars have favorably discussed proposals to promote<br />pharmaceutical innovation through a public fund rather than market<br />monopolies. On November 9th, Peter Pitts will present an important<br />criticism of these proposals.<br /><br />Peter Pitts is perhaps best know to members of this list as one of<br />the “wonks” at the pharmaceutical blog Drugwonks.com. He was the<br />Chief Messaging Officer at the FDA from 2002-2004, and he is co-<br />founder of the Center for Medicine in the Public Interest. Formerly<br />a senior fellow for health care studies at the Pacific Research<br />Institute, he is currently senior vice president for health affairs<br />at Manning, Selvage & Lee.<br /><br />Pitts notes that proposed medical innovation prize funds would reward<br />pharmaceutical innovations in proportion to the incremental health<br />benefits they provide. However, Pitts will argue, evidence of<br />incremental health benefits provided by new drugs is expensive and<br />difficult to obtain and often inadequate. Trends toward<br />pharmacogentic technology and improved diagnostic tools suggest that<br />determining the overall health benefits of future pharmaceutical<br />developments will be even more difficult, if not impossible, as new<br />drugs will be evaluated on a basis more narrowly tailored to<br />individual patients than to the population as a whole. As a result,<br />compensation for pharmaceutical innovators is most appropriately<br />determined by the spending choices of well-informed consumers who<br />know their own medical situations best.<br /><br />We encourage all to attend what will certainly be an insightful and<br />lively presentation and discussion. If you would like to join us,<br />please RSVP your name, title, organization and contact information to<br />ben.krohmal@cptech.org or 202-332-2670.<div class="blogger-post-footer"><img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/34485579-115920532722781874?l=cptechstaff.blogspot.com'/></div>Julie Patelhttp://www.blogger.com/profile/09449508724143352389noreply@blogger.com0tag:blogger.com,1999:blog-34485579.post-1158354073137210082006-09-15T13:58:00.000-07:002006-09-15T14:03:01.973-07:00Patent Buy-Outs for Global Disease InnovationThe Consumer Project on Technology (CPTech) is hosting a seminar by<br /><span style="font-weight: bold;">Kevin Outterson on "Patent Buy-Outs for Global Disease Innovation."</span><br /><br />Many of you received the initial invitation when this event was<br />scheduled for May 10th and then cancelled. It has now been rescheduled:<br /><br />Date: Tuesday October 10, 2006<br />Time: 12:30-2pm<br />Venue: 1621 Connecticut Avenue Suite 500, Washington, DC 20009<br /><br />Kevin Outterson is an Associate Professor of Law at West Virginia University. He is also a member of the American Health Lawyer's Association's FDA Task Force. In 2004, Governor Wise appointed him to a 4 year term with the West Virginia Pharmaceutical Cost Management Council. Some of his professional papers include, "Patent Buy-Outs for Global Disease Innovations for low and middle-income countries" and "Fair followers: Expanding access to generic pharmaceuticals for low-income populations."<br /><br />Professor Outterson's presentation will discuss the concept of patent buy-outs to facilitate generic competition.<br /><br />Some 80% to 90% of the global sales of patented pharmaceuticals occur in the 30 wealthy countries which are members of the Organization for Economic Cooperation and Development (OECD), roughly similar to the World Bank's definition of 29 high-income countries. Pharmaceutical markets for patented products largely follow the money. The mismatch between global pharmaceutical markets and global disease burdens leads to an interesting opportunity. Patented pharmaceuticals could be offered to more than 84% of the world's population at generic prices. (Only high-income country patients would bear pharmaceutical patent rents).<br /><br />The gain in health from increasingly affordable pharmaceuticals would be considerable. The primary disadvantage of this plan would be a quite small reduction in global R&D cost recovery; but even this small deficit could be restored to the companies through a carefully designed patent buy-out mechanism.<div class="blogger-post-footer"><img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/34485579-115835407313721008?l=cptechstaff.blogspot.com'/></div>Julie Patelhttp://www.blogger.com/profile/09449508724143352389noreply@blogger.com1tag:blogger.com,1999:blog-34485579.post-1158352179407962082006-09-15T13:24:00.000-07:002006-09-15T13:41:27.220-07:00Social Justice and New Approaches to Promoting Pharmaceutical InnovationThe Consumer Project on Technology (CPTech) is hosting a seminar by Thomas Pogge on <span style="font-weight: bold;">“Social Justice and New Approaches to Promoting Pharmaceutical Innovation.”</span><br /><br />Date: Tuesday, October 17th, 2006<br />Time: 12-1:30pm<br />Venue: 1621 Connecticut Avenue Suite 500, Washington, DC 20009<br /><br />Several proposals have been put forth suggesting ways to promote productive pharmaceutical innovation without relying on drug monopolies that lead to exorbitant prices. On October 17th, CPTech will host Thomas Pogge’s presentation of one such proposal and discussion of the need for pharmaceutical IP reform from the perspective of social justice.<br /><br />Pogge is a professor of political science and philosophy at Columbia University and the Australian National University. He received his PhD from Harvard under the supervision of John Rawls and is the author of World Poverty and Human Rights. Pogge’s work is considered seminal in the field of global justice, and he has recently devoted considerable research to intellectual property as it relates to access to medicine.<br /><br />According to Pogge,<br />“The rules should be redesigned so that the development of any new essential drug is rewarded in proportion to its impact on the global disease burden (not through monopoly rents). This reform would bring down drug prices worldwide close to their marginal cost of production and would powerfully stimulate pharmaceutical research into currently neglected diseases concentrated among the poor. Its feasibility shows that the existing medical-patent regime (TRIPS as supplemented by bilateral agreements) is severely unjust — and its imposition a human rights violation on account of the avoidable mortality and morbidity it foreseeably produces.”<br /><br />From “Human Rights and Global Health: A Research Program” in Ethics and Infectious Disease (Oxford: Blackwell 2006), 285-314.<br /><br />We encourage all to attend what will certainly be a fascinating and insightful presentation and discussion. If you would like to join us, please RSVP your name, title, organization and contact information to <span style="font-weight: bold;">ben.krohmal@cptech.org</span> or 202 332 2670.<div class="blogger-post-footer"><img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/34485579-115835217940796208?l=cptechstaff.blogspot.com'/></div>Julie Patelhttp://www.blogger.com/profile/09449508724143352389noreply@blogger.com0